Nilanjana Ghosh1, Priyanka Choudhury1, Elavarasan Subramani1, Dipanjan Saha2, Sayoni Sengupta2, Mamata Joshi3, Rintu Banerjee4, Sushmita Roychowdhury5, Parthasarathi Bhattacharyya2, Koel Chaudhury6. 1. School of Medical Science and Technology (SMST), Indian Institute of Technology Kharagpur, Kharagpur, 721302, India. 2. Institute of Pulmocare and Research, Kolkata, India. 3. National Facility for High-field NMR, Tata Institute of Fundamental Research, Mumbai, India. 4. Department of Agricultural & Food Engineering, Indian Institute of Technology Kharagpur, Kharagpur, India. 5. Apollo Gleneagles Hospitals, Kolkata, India. 6. School of Medical Science and Technology (SMST), Indian Institute of Technology Kharagpur, Kharagpur, 721302, India. koel@smst.iitkgp.ac.in.
Abstract
INTRODUCTION: Asthma-chronic obstructive pulmonary disease (COPD) overlap, termed as ACO, is a complex heterogeneous disease without any clear diagnostic or therapeutic guidelines. The pathophysiology of the disease, its characteristic features, and existence as a unique disease entity remains unclear. Individuals with ACO have a faster lung function decline, more frequent exacerbations, and worse quality of life than those with COPD or asthma alone. OBJECTIVES: The present study aims to determine whether ACO has a distinct metabolic profile in comparison to asthma and COPD. METHODS: Two different groups of patients were recruited as discovery (D) and validation (V) cohorts. Serum samples obtained from moderate and severe asthma patients diagnosed as per GINA guidelines [n = 34(D); n = 32(V)], moderate and severe COPD cases identified by GOLD guidelines [n = 30(D); 32(V)], ACO patients diagnosed by joint GOLD and GINA guidelines [n = 35(D); 40(V)] and healthy controls [n = 33(D)] were characterized using nuclear magnetic resonance (NMR) spectrometry. RESULTS: Multivariate and univariate analysis indicated that 12 metabolites [lipid, isoleucine, N-acetylglycoproteins (NAG), valine, glutamate, citric acid, glucose, L-leucine, lysine, asparagine, phenylalanine and histidine] were dysregulated in ACO patients when compared with both asthma and COPD. These metabolites were further validated in a fresh cohort of patients, which again exhibited a similar expression pattern. CONCLUSIONS: Our findings suggest that ACO has an enhanced energy and metabolic burden associated with it as compared to asthma and COPD. It is anticipated that our results will stimulate researchers to further explore ACO and unravel the pathophysiological complexities associated with the disease.
INTRODUCTION:Asthma-chronic obstructive pulmonary disease (COPD) overlap, termed as ACO, is a complex heterogeneous disease without any clear diagnostic or therapeutic guidelines. The pathophysiology of the disease, its characteristic features, and existence as a unique disease entity remains unclear. Individuals with ACO have a faster lung function decline, more frequent exacerbations, and worse quality of life than those with COPD or asthma alone. OBJECTIVES: The present study aims to determine whether ACO has a distinct metabolic profile in comparison to asthma and COPD. METHODS: Two different groups of patients were recruited as discovery (D) and validation (V) cohorts. Serum samples obtained from moderate and severe asthmapatients diagnosed as per GINA guidelines [n = 34(D); n = 32(V)], moderate and severe COPD cases identified by GOLD guidelines [n = 30(D); 32(V)], ACO patients diagnosed by joint GOLD and GINA guidelines [n = 35(D); 40(V)] and healthy controls [n = 33(D)] were characterized using nuclear magnetic resonance (NMR) spectrometry. RESULTS: Multivariate and univariate analysis indicated that 12 metabolites [lipid, isoleucine, N-acetylglycoproteins (NAG), valine, glutamate, citric acid, glucose, L-leucine, lysine, asparagine, phenylalanine and histidine] were dysregulated in ACO patients when compared with both asthma and COPD. These metabolites were further validated in a fresh cohort of patients, which again exhibited a similar expression pattern. CONCLUSIONS: Our findings suggest that ACO has an enhanced energy and metabolic burden associated with it as compared to asthma and COPD. It is anticipated that our results will stimulate researchers to further explore ACO and unravel the pathophysiological complexities associated with the disease.
Authors: Olivier Cloarec; Marc E Dumas; Johan Trygg; Andrew Craig; Richard H Barton; John C Lindon; Jeremy K Nicholson; Elaine Holmes Journal: Anal Chem Date: 2005-01-15 Impact factor: 6.986
Authors: Mahesh J Patel; Bryan C Batch; Laura P Svetkey; James R Bain; Christy Boling Turer; Carol Haynes; Michael J Muehlbauer; Robert D Stevens; Christopher B Newgard; Svati H Shah Journal: OMICS Date: 2013-10-11
Authors: Baljit K Ubhi; John H Riley; Paul A Shaw; David A Lomas; Ruth Tal-Singer; William MacNee; Julian L Griffin; Susan C Connor Journal: Eur Respir J Date: 2011-12-19 Impact factor: 16.671
Authors: Bettina Levänen; Nirav R Bhakta; Patricia Torregrosa Paredes; Rebecca Barbeau; Stefanie Hiltbrunner; Joshua L Pollack; C Magnus Sköld; Magnus Svartengren; Johan Grunewald; Susanne Gabrielsson; Anders Eklund; Britt-Marie Larsson; Prescott G Woodruff; David J Erle; Åsa M Wheelock Journal: J Allergy Clin Immunol Date: 2013-01-16 Impact factor: 10.793
Authors: Vladimir Koblizek; Jan Chlumsky; Vladimir Zindr; Katerina Neumannova; Jakub Zatloukal; Jaroslav Zak; Vratislav Sedlak; Jana Kocianova; Jaromir Zatloukal; Karel Hejduk; Sarka Pracharova Journal: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub Date: 2013-05-24 Impact factor: 1.245
Authors: Klaus F Rabe; Suzanne Hurd; Antonio Anzueto; Peter J Barnes; Sonia A Buist; Peter Calverley; Yoshinosuke Fukuchi; Christine Jenkins; Roberto Rodriguez-Roisin; Chris van Weel; Jan Zielinski Journal: Am J Respir Crit Care Med Date: 2007-05-16 Impact factor: 21.405
Authors: Yang Xiang; Hangyu Ji; Yujia Zhou; Fang Li; Jingcheng Du; Laila Rasmy; Stephen Wu; W Jim Zheng; Hua Xu; Degui Zhi; Yaoyun Zhang; Cui Tao Journal: J Med Internet Res Date: 2020-07-31 Impact factor: 5.428